Moleculin Biotech (MBRX) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

MBRX Moleculin Biotech

Watchlist

2.8300
+0.1600+5.99%

Close Nov 21 16:00 ET

2.8300
0.00000.00%

Post 17:20 ET

8.50MMarket Cap-236P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Moleculin Biotech Advances Annamycin for AML Treatment
TipRanksNov 18 08:48 ET
New Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AML
PR NewswireNov 18 08:15 ET
Express News | Moleculin Amends Clinical Trial Protocol With FDA For Its Phase 3 Trial Of Annamycin In Combination With Cytarabine; Amended Protocol Accelerates Unblinding Of Prelim. Primary Efficacy Data And Safety/Tolerability Of Three Arms At First 45 Subjects
BenzingaNov 14 08:20 ET
Express News | Moleculin Accelerates Planned Unblinded Data Readout for Miracle Phase 3 R/R Acute Myeloid Leukemia (Aml) Pivotal Trial to H2 2025
ReutersNov 14 08:15 ET
Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025
Moleculin BiotechNov 14 00:00 ET
Moleculin Biotech Unveils New Corporate Presentation
TipRanksNov 12 10:13 ET

Comments

Trytosaveabit

Nov 18 07:17

Update

$Moleculin Biotech (MBRX.US)$ New Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AML
2 MINUTES AGO, 8:15 AM EST
VIA PR NEWSWIRE
Preclinical data accepted for online publication at ASH Annual Meeting reveal significant activity of Annamycin in Venetoclax resistant AML model
New preliminary clinical results show Annamycin plus Ara-C achieved 60% CR/CRi in subjects who were relapsed from or refractory to Venetoclax regimens; more than 4 times greater than published h...

Trytosaveabit

Nov 14 07:18

Update

$Moleculin Biotech (MBRX.US)$ Reuters· 3 mins ago
Moleculin Accelerates Planned Unblinded Data Readout for Miracle Phase 3 R/R Acute Myeloid Leukemia (Aml) Pivotal Trial to H2 2025

Jaguar8

Nov 14 07:15

NEWS

$Moleculin Biotech (MBRX.US)$
Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025
Moleculin Biotech (MBRX) has amended its Phase 3 MIRACLE trial protocol for Annamycin in combination with Cytarabine (AnnAraC) for treating relapsed/refractory AML. The amended protocol allows for earlier unblinding of preliminary efficacy data at 45 subjects in H2 2025, accelerating from the previous 2026 timeline. The trial will use...

Trytosaveabit

Nov 12 07:13

Update

$Moleculin Biotech (MBRX.US)$ Moleculin Receives Institutional Review Board Approval for Miracle Phase 3 Pivotal Trial of Annamycin in Combination With Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (Aml)